[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-tension-glaucoma-ntg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-tension-glaucoma-ntg":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100620196","phase-2-single-site-pilot-study-evaluating-the-effect-of-qls-111-ophthalmic-solution-on-posterior-perfusion-and-vessel-dilation-100620196",false,"NCT07354477","Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","(PENGUIN)","Inclusion Criteria:\n\n* Diagnosis of mild to moderate OAG, mild to moderate NTG, or stable NPDR in at least one eye.\n* Corrected visual acuity in each eye +1.0 logMAR or better by early treatment diabetic retinopathy study (ETDRS) in each eye (equivalent to 20\u002F200).\n* Able and willing to give signed informed consent and follow study instructions.\n\nExclusion Criteria:\n\n* History of active ocular disease other than mild to moderate OAG, mild to moderate NTG, or stable NPDR.\n* Patient is using more than 1 ocular hypotensive topical medication for intraocular pressure (IOP) control (prior MIGS and\u002For laser trabeculoplasty to control IOP is allowed if done at least 3 months from Screening (Visit 1).\n* Use of TO β-blockers (i.e. timolol) within 3 months prior to Screening.\n* Is noncompliant with current ocular anti-hypotensive medications and\u002For unwilling to be compliant throughout the study.\n* Clinically significant severe retinal disease in either eye that will require treatment during the study (e.g., proliferative diabetic retinopathy, exudative, or severe non-exudative macular degeneration). NOTE: background diabetic retinopathy (BDR) as required for the NPDR subjects is allowed if in the Investigator's opinion the BDR is stable and is expected to remain stable during the duration of the study.\n* Anti-VEGF or TO steroid treatment within 3 months prior to Screening or expected treatment while participating in this study. Prior diabetic macular edema (DME) history is allowed if adequately controlled with treatment (anti-VEGFs and steroids not within last 3 months prior to Screening), regimen is stable, and not expected to change during the study. - Corneal pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, and bullae) in either eye that would inhibit accurate IOP measurements.\n* Previously diagnosed, clinically significant systemic or psychiatric disease (e.g., myasthenia gravis, hepatic, renal, endocrine, pulmonary, or cardiovascular disorders) which might compromise the study results or subject safety. For the purpose of this study previously diagnosed, clinically significant renal disease that should be excluded from enrollment will be defined as Stages 3-5 kidney disease and\u002For an estimated glomerular filtration rate (eGFR) of ≤59.\n* Use of calcium channel blockers.\n* Labile hypertension and\u002For hypotension that is inadequately controlled,","ALL","18 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG",[27,28,29],"Non-proliferative Diabetic Retinopathy (NPDR)","Open-angle Glaucoma (OAG)","Normal Tension Glaucoma (NTG)",[31,32,33],"glaucoma","diabetic retinopathy","vessel dilation","RECRUITING","2026-02-21",{"date":37,"type":38},"2026-02-24","ACTUAL",{"date":40,"type":38},"2026-02-20",{"date":42,"type":21},"2026-06",{"name":44,"class":45},"Qlaris Bio, Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":46},"100616072","dslt-in-normal-tension-glaucoma-ntg-asian-eyes-100616072","NCT07300852","DSLT in Normal Tension Glaucoma (NTG) Asian Eyes","The Effectiveness of DSLT in Asian Normal Tension Glaucoma Patients","Inclusion Criteria:\n\n* Asian descent\n* NTG diagnosis: glaucomatous optic neuropathy in patients with IOP measurements consistently lower than 21 mmHg\n* Mean deviation (MD) of the visual field between 0 to -12dB\n* No significant central vision loss within 5 degrees within 5th percentile\n* Age ≥20 years\n* NTG patients who are medically controlled on 1-3 medications and safe to wash out or IOP is still insufficient from medications and safe to washout\n* Shaffer grade II or more on 3 of the 4 quadrants\n* Central corneal thickness (CCT) 450-600µm\n* All participants are able to provide written informed consent before participation\n\nExclusion Criteria:\n\n* Angle closure glaucoma or narrow angle status post laser peripheral iridotomy (LPI), or any other open angle glaucoma excluding NTG\n* History of SLT within last 2 years\n* History intraocular surgery including refractive surgery, except for history of cataract surgery that has been greater than 1 year\n* Patients anticipating cataract surgery during the study follow-up period\n* Unable to have DSLT procedure due to pre-limbal findings\n* Any presence of relevant ocular diseases including retinal disease with no confirmed cure","20 Years",{"count":56,"type":21},40,[58],"NA","The goal of this clinical trial is to evaluate the efficacy of direct selective laser trabeculoplasty (DSLT) or laser treatment in Asian patients with normal tension glaucoma. The main question it aims to answer is:\n\nDoes the DSLT reduce intraocular pressure (IOP) and medication use in Asian NTG subjects? Participants will attend routine follow-up visits with their eye surgeon and glaucoma testing such as optical coherence tomography (OCT) imaging and visual field test(s) after the laser study treatment.",[29,61,62,63],"Glaucoma","Open Angle Glaucoma (OAG)","Glaucoma, Open Angle",[65,66,67,61,68,69,70,71,72,73,74],"DSLT","Direct Selective Laser Trabeculoplasty","NTG","Normal Tension Glaucoma","BELKIN Vision Eagle","Glaucoma laser treatment","Asian glaucoma","Intraocular pressure","SLT alternative","Glaucoma medications reduction","NOT_YET_RECRUITING","2025-12-20",{"date":78,"type":38},"2025-12-24",{"date":80,"type":21},"2026-01-01",{"date":82,"type":21},"2028-03-31",{"name":84,"class":85},"Ngoc Nguyen Inc.","OTHER",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":104,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100598776","optic-nerve-head-evaluation-through-multimodal-blood-flow-analysis-a-prospective-observational-multi-center-study-100598776","NCT07075887","Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study","FlowONH","Inclusion Criteria:\n\n* Participant (or parents\u002Flegal representative\u002Ftutor for minors) is willing and able to give informed consent for participation in the study\n* patients affected by acute ONH edema (NAION, papilledema, optic neuritis)\n* patients affected by acute pseudoedema (LHON)\n* patients affected by chronic pseudoedema (LHON, ODD)\n* patients affected by chronic ONH neuropathies (NTG, DOA, WS) non- affected eyes in each optic neuropathy patient\n\nExclusion Criteria:\n\n* any other ONH disease or neurological \u002Fretinal disease impairing the evaluation of the ONH;\n* evidence of media opacities affecting the quality of the vascular assessment;\n* patients affected Alzheimer\u002FParkinson disease will be considered separately","12 Years",{"count":95,"type":21},70,"OBSERVATIONAL","OCT-A and eco-colordoppler are technologies which enable optic nerve head (ONH) blood perfusion detection. The aim of the study is to assess ONH vascular and structural components in optic neuropathies with and without ONH edema or pseudo-edema with OCT-A, and analyze ONH blood-flow with eco-colordoppler.",[99,100,101,102,103,29],"Neuro-Ophthalmology","Optic Neuropathies","Optic Atrophy, Hereditary, Leber","Optic Neuropathy, Anterior Ischemic","Optic Disc Drusen",[105,106,107],"oct-a","ecocolordoppler","optic neuropathies","2025-07-10",{"date":110,"type":38},"2025-07-20",{"date":112,"type":21},"2025-10",{"date":114,"type":21},"2028-10",{"name":116,"class":85},"Barboni"]